ID27843A - Substitusi 1, 8-naftiridin-4(ih)-on sebagai penghambat fosfodiesterase 4 - Google Patents

Substitusi 1, 8-naftiridin-4(ih)-on sebagai penghambat fosfodiesterase 4

Info

Publication number
ID27843A
ID27843A IDW20010315A ID20010315A ID27843A ID 27843 A ID27843 A ID 27843A ID W20010315 A IDW20010315 A ID W20010315A ID 20010315 A ID20010315 A ID 20010315A ID 27843 A ID27843 A ID 27843A
Authority
ID
Indonesia
Prior art keywords
hospitaler
naftiridin
phosphodiesterase
substitution
Prior art date
Application number
IDW20010315A
Other languages
English (en)
Indonesian (id)
Inventor
Edward Fox Kleinman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID27843A publication Critical patent/ID27843A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20010315A 1998-08-11 1999-08-05 Substitusi 1, 8-naftiridin-4(ih)-on sebagai penghambat fosfodiesterase 4 ID27843A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9617698P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
ID27843A true ID27843A (id) 2001-04-26

Family

ID=22256080

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010315A ID27843A (id) 1998-08-11 1999-08-05 Substitusi 1, 8-naftiridin-4(ih)-on sebagai penghambat fosfodiesterase 4

Country Status (44)

Country Link
US (1) US6174895B1 (de)
EP (1) EP1104420B1 (de)
JP (1) JP2002522541A (de)
KR (1) KR20010072368A (de)
CN (1) CN1312810A (de)
AP (1) AP2001002068A0 (de)
AR (1) AR015557A1 (de)
AT (1) ATE229955T1 (de)
AU (1) AU4924999A (de)
BG (1) BG105321A (de)
BR (1) BR9912902A (de)
CA (1) CA2340180A1 (de)
CO (1) CO5130004A1 (de)
CZ (1) CZ2001485A3 (de)
DE (1) DE69904602T2 (de)
DK (1) DK1104420T3 (de)
DZ (1) DZ2866A1 (de)
EA (1) EA200100124A1 (de)
EE (1) EE200100085A (de)
ES (1) ES2188194T3 (de)
GE (1) GEP20033029B (de)
GT (1) GT199900128A (de)
HK (1) HK1038917A1 (de)
HN (1) HN1999000130A (de)
HR (1) HRP20010107A2 (de)
HU (1) HUP0103466A3 (de)
ID (1) ID27843A (de)
IL (1) IL140868A0 (de)
IS (1) IS5815A (de)
MA (1) MA26669A1 (de)
NO (1) NO20010684L (de)
NZ (1) NZ509297A (de)
OA (1) OA11591A (de)
PA (1) PA8480001A1 (de)
PE (1) PE20000950A1 (de)
PL (1) PL346005A1 (de)
PT (1) PT1104420E (de)
SK (1) SK1822001A3 (de)
SV (1) SV1999000120A (de)
TN (1) TNSN99155A1 (de)
TR (1) TR200100433T2 (de)
TW (1) TW542835B (de)
WO (1) WO2000009504A1 (de)
ZA (1) ZA200101040B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
JP2004532809A (ja) * 2000-11-02 2004-10-28 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク ホスホジエステラーゼ4型を阻害することによって、神経系の再生および修復を刺激するための方法
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
WO2003077857A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
KR100454750B1 (ko) * 2002-06-20 2004-11-03 삼성에스디아이 주식회사 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자
CA2506949A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10349497A1 (de) * 2003-10-23 2005-05-25 Bayer Cropscience Ag N-substituierte Pyrazolylcarboxanilide
JP2007517828A (ja) * 2004-01-17 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道の疾患を治療するための置換プテリジンの使用
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (de) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Kristalline form eines dihydropteridionderivats
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN104507912B (zh) * 2012-08-08 2016-09-28 默克专利股份公司 (氮杂-)异喹啉酮衍生物
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU165405B (de) * 1972-06-29 1974-08-28
US3856800A (en) * 1973-02-26 1974-12-24 Sterling Drug Inc Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates
US3882132A (en) * 1973-03-08 1975-05-06 Sterling Drug Inc Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs
WO1996006843A1 (en) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤

Also Published As

Publication number Publication date
HRP20010107A2 (en) 2002-02-28
ZA200101040B (en) 2003-01-07
ES2188194T3 (es) 2003-06-16
SV1999000120A (es) 2000-09-05
SK1822001A3 (en) 2002-08-06
DK1104420T3 (da) 2003-01-13
CA2340180A1 (en) 2000-02-24
US6174895B1 (en) 2001-01-16
AP2001002068A0 (en) 2001-03-31
PE20000950A1 (es) 2000-09-27
CN1312810A (zh) 2001-09-12
AU4924999A (en) 2000-03-06
NO20010684D0 (no) 2001-02-09
BG105321A (en) 2001-12-29
IS5815A (is) 2001-01-16
ATE229955T1 (de) 2003-01-15
DE69904602D1 (en) 2003-01-30
MA26669A1 (fr) 2004-12-20
EP1104420A1 (de) 2001-06-06
HK1038917A1 (zh) 2002-04-04
DZ2866A1 (fr) 2003-12-01
CO5130004A1 (es) 2002-02-27
NO20010684L (no) 2001-04-09
BR9912902A (pt) 2001-05-08
GT199900128A (es) 2001-01-30
KR20010072368A (ko) 2001-07-31
PL346005A1 (en) 2002-01-14
HUP0103466A3 (en) 2002-11-28
CZ2001485A3 (cs) 2002-05-15
DE69904602T2 (de) 2003-04-30
EA200100124A1 (ru) 2001-10-22
HUP0103466A2 (hu) 2002-02-28
OA11591A (en) 2004-07-30
EE200100085A (et) 2002-08-15
HN1999000130A (es) 2000-11-22
TW542835B (en) 2003-07-21
GEP20033029B (en) 2003-07-25
IL140868A0 (en) 2002-02-10
EP1104420B1 (de) 2002-12-18
TNSN99155A1 (fr) 2005-11-10
TR200100433T2 (tr) 2001-07-23
PA8480001A1 (es) 2000-09-29
WO2000009504A1 (en) 2000-02-24
PT1104420E (pt) 2003-03-31
JP2002522541A (ja) 2002-07-23
AR015557A1 (es) 2001-05-02
NZ509297A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
DE69907964D1 (de) 1,2-annelierte chinolinderivate
HUP0100779A3 (en) Novel derivatives of 3,3-diphenylpropylamines
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
ID27595A (id) SENYAWA-SENYAWA PIROLO (2,3-d) PIRIMIDINA
PT1087970E (pt) Compostos pirrolo¬2,3-d|pirimidina
NO20010684D0 (no) Substituert 1,8-Naphthyridin-4(1H)-on som fosfodiesterase 4 inhibitorer
ID26310A (id) Produksi kontinyu 1,3-dioksolan-2-ona
TR199801367A3 (tr) 5H- tiazol (3,2-a) pirimidin türevleri
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
EE200000447A (et) 1,3,4-oksadiasolooni derivaadid
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
ATE234839T1 (de) 4,5-azolo-oxindole
PT1129079E (pt) Derivados de triazina 2,4-dissubstituidos
EP1156040A4 (de) 2,4-dioxo-5-arylidenimido-1,3-pyrimidine
ID26368A (id) Turunan-turunan 2 deoksi higromisin
NO20015397D0 (no) 1,5-Benzodiazepin-derivater
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
ATA16399A (de) Schmuckstück-set
FI980405A0 (fi) Industriellt, kontinuerligt foerfarande foer framstaellning av "gravkalk"
PL337907A1 (en) Novel chemical compounds - derivatives of symmetrical 1,3,5-triazine
PL325446A1 (en) Novel ferrocomplexes of 1:2 type - derivatives of 1,5 diphenylformazane
ZA9811564B (en) Derivatives of 1,3,4-oxadiazolone